| Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex RL Wade, P Chaudhari, JL Natoli, RJ Taylor, BH Nathanson, DL Horn Diagnostic Microbiology and Infectious Disease 76 (3), 361-367, 2013 | 61 | 2013 |
| Improving medication adherence and health care outcomes in a commercial population through a community pharmacy OE Akinbosoye, MS Taitel, J Grana, J Hill, RL Wade Population health management 19 (6), 454-461, 2016 | 53 | 2016 |
| Orphan drug expenditures in the United States: a historical and prospective analysis, 2007–18 V Divino, M DeKoven, M Kleinrock, RL Wade, S Kaura Health Affairs 35 (9), 1588-1594, 2016 | 44 | 2016 |
| Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib CC Chen, K Parikh, S Abouzaid, L Purnomo, CB McGuiness, M Hussein, ... Journal of managed care & specialty pharmacy 23 (2), 236-246, 2017 | 40 | 2017 |
| Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors DM Hines, P Rane, J Patel, DJ Harrison, RL Wade Vascular Health and Risk Management, 409-418, 2018 | 35 | 2018 |
| Economic and clinical burden of relapsed and/or refractory active treatment episodes in patients with acute myeloid leukemia (AML) in the USA: a retrospective analysis of a … BJ Pandya, CC Chen, BC Medeiros, CB McGuiness, S Wilson, ... Advances in Therapy 36, 1922-1935, 2019 | 23 | 2019 |
| Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as … RL Wade, SL Kindermann, Q Hou, ME Thase Journal of managed care pharmacy 20 (1), 76-85, 2014 | 23 | 2014 |
| Patient carrying time, confidence, and training with epinephrine autoinjectors: the RACE survey J Portnoy, RL Wade, C Kessler The Journal of Allergy and Clinical Immunology: In Practice 7 (7), 2252-2261, 2019 | 22 | 2019 |
| Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database BJ Pandya, CC Chen, BC Medeiros, CB McGuiness, SD Wilson, ... Journal of Managed Care & Specialty Pharmacy 26 (7), 849-859, 2020 | 21 | 2020 |
| Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor … RP Frantz, JW Hill, CA Lickert, RL Wade, MR Cole, Y Tsang, W Drake III Pulmonary Circulation 10 (1), 2045894019880086, 2020 | 21 | 2020 |
| Treatment adherence and persistence among HIV-1 patients newly starting treatment DM Hines, Y Ding, RL Wade, A Beaubrun, JP Cohen Patient preference and adherence, 1927-1939, 2019 | 21 | 2019 |
| Implementation of a pharmacy-based adult vaccine benefit: recommendations for a commercial health plan benefit KJ Ko, RL Wade, HT Yu, RM Miller, B Sherman, J Goad Journal of Managed Care Pharmacy 20 (3), 273-282, 2014 | 21 | 2014 |
| Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database D Bhowmik, DM Hines, M Intorcia, RL Wade Journal of medical economics 21 (6), 622-628, 2018 | 20 | 2018 |
| Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension LA Miller, R Wade, D Dai, MJ Cziraky, K Ramaswamy, S Panjabi Current Medical Research and Opinion 26 (6), 1307-1320, 2010 | 19 | 2010 |
| Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States JD Guo, P Hlavacek, T Poretta, G Wygant, D Lane, M Gorritz, X Wang, ... Journal of Thrombosis and Thrombolysis 50, 386-394, 2020 | 17 | 2020 |
| Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis V Divino, M DeKoven, M Kleinrock, RL Wade, T Kim, S Kaura Orphanet journal of rare diseases 11, 1-8, 2016 | 17 | 2016 |
| Survival of US Medicare patients with advanced non-small cell lung cancer by line of therapy. JR Penrod, B Korytowsky, A Petrilla, JP Wisnivesky, C Craver, M Salvati, ... Journal of Clinical Oncology 32 (15_suppl), 6582-6582, 2014 | 17 | 2014 |
| Comparison of adverse events and hospital length of stay associated with various amphotericin B formulations: sequential conventional amphotericin b/lipid versus lipid-only … RL Wade, P Chaudhari, JL Natoli, RJ Taylor, BH Nathanson, D Horn Pharmacy and Therapeutics 38 (5), 278, 2013 | 17 | 2013 |
| Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID … RM Bergenstal, LP Garrison Jr, LA Miller, L Hou, A Blickensderfer, ... Current medical research and opinion 27 (12), 2335-2342, 2011 | 17 | 2011 |
| Two-year adherence and costs for biologic therapy for rheumatoid arthritis. BS Stolshek, S Wade, A Mutebi, RL Wade, J Yeaw The American journal of managed care 24 (8 Spec No.), SP315-SP321, 2018 | 16 | 2018 |
